SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-015729
Filing Date
2022-08-09
Accepted
2022-08-09 06:45:29
Documents
14
Period of Report
2022-08-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K verv-20220803.htm   iXBRL 8-K 69314
2 EX-99.1 verv-ex99_1.htm EX-99.1 192178
3 GRAPHIC img74140242_0.jpg GRAPHIC 2993
  Complete submission text file 0000950170-22-015729.txt   411112

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT verv-20220803_lab.xml EX-101.LAB 18598
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT verv-20220803.xsd EX-101.SCH 2497
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT verv-20220803_pre.xml EX-101.PRE 11600
8 EXTRACTED XBRL INSTANCE DOCUMENT verv-20220803_htm.xml XML 4894
Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 221146299
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences